BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022. Currently, the COPD market is dominated by Boehringer Ingelheim/Pfizer's long-acting muscarinic antagonist (LAMA) Spiriva and GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) Advair/Seretide/Adoair. In 2012, total sales of these two market leaders constituted nearly two-thirds of COPD sales. However, following the launch of new agents, particularly those that offer advantages in dosing, their combined market share will diminish to less than 15 percent in 2022.
The Pharmacor advisory service entitled Chronic Obstructive Pulmonary Disease finds that the market for COPD will increase from nearly $10 billion in 2012 to $14 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Five fixed-dose combination inhalers comprised of a LABA and a LAMA are forecasted to launch over the next ten years and this new drug class will collectively garner over 35 percent market share in 2022. Among these novel combinations, GlaxoSmithKline/Theravance's Anoro and Boehringer Ingelheim's olodaterol/tiotropium are expected to experience the greatest success, totaling nearly $4 billion in major-market sales in 2022.
"The clinical trial data for LABA/LAMAs continue to be promising and these combination products will provide the convenience of delivering the two major bronchodilator classes that are recommended as first-line maintenance options in treatment guidelines," said Decision Resources Senior Director Joanna Kim, M.Ed.
The findings also reveal that GlaxoSmithKline/Theravance's Breo/Relvar will perform strongly and act as another key growth driver, alongside the LABA/LAMAs, in the COPD market. Breo/Relvar's once-daily administration will be the first to offer dosing improvement over Advair which, together with efficacy that is comparable to Advair, will challenge Advair's dominance in all major markets.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
|SOURCE Decision Resources|
Copyright©2012 PR Newswire.
All rights reserved